CD19 and Miyoshi myopathy: In a clinical setting of MM patients, the safety and efficacy of a sequential treatment regimen consisting of autologous stem cell transplantation followed by anti-CD19 and anti-BCMA CAR T-cell infusion plus lenalidomide maintenance until disease progression was investigated.